Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyvox Medicare “Add-On” Payments Denied; CMS Wary Of Precedent

Executive Summary

The denial of Medicare "add-on" payments for Pharmacia's Zyvox reflects CMS' desire to avoid a precedent that could make numerous older therapies eligible for enhanced reimbursement, the agency said in an Aug. 1 final rule implementing changes to the hospital in-patient payment system
Advertisement

Related Content

Guilford Gliadel Denied Add-On Payments By CMS; New IL-2 Code Proposed
Guilford Gliadel Denied Add-On Payments By CMS; New IL-2 Code Proposed
Xigris Medicare “Add-On” Payments Approved; CMS Estimates 50,000 Cases
Xigris Medicare “Add-On” Payments Approved; CMS Estimates 50,000 Cases
Xigris Medicare “Add-On” Payments Approved; CMS Estimates 50,000 Cases
Pfizer’s Friendly Tack: McKinnell Shares Credit With Hassan, Offers No. 2 Spot
Zyvox Not Major Treatment Expense, CMS Says; Add-On Payments Denied
Zyvox Not Major Treatment Expense, CMS Says; Add-On Payments Denied
Advertisement
UsernamePublicRestriction

Register

PS040284

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel